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Intestinal absorptionAbstract The purpose of this study was to develop nanosuspension based on combinative technol-
ogy to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihyperten-
sive agent with limited oral bioavailability. Two combinative approaches were employed and then
characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied
using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a
combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula
exhibited particle size of 469.9 nm and zeta potential of 19.1 mV, which was subjected to
ex vivo studies. The ﬂux and apparent permeability coefﬁcient in intestine from OLM nanosuspen-
sion was higher than the plain drug, thereby suggesting better drug delivery.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug solubility is a crucial factor limiting the therapeutic advan-
tage of many potent drugs because of low oral bioavailability.
The conventional approach to enhance oral bioavailability of
drugs with very low aqueous solubility includes use of co-sol-
vents, salt formation, pH adjustment, emulsions and micellar
dispersions, micronization and complexationwith cyclodextrins
(Lawrence and Rees, 2000; Nakano, 2000; Stella and Rajewski,
1997). These approaches are useful, but possess some limitations
such as the use of large amount of excipients and sophisticated
equipment. An alternative method is nanonization of drug
and stabilization using stabilizers, termed as nanosuspension
(particle size in nanometer range). Nanosuspensions are
reported to increase saturation solubility due to reduced particle
Figure 1 HPLC chromatogram of olmesartan medoxomil.
Figure 2 Calibration curve of OLM using HPLC–UV method.
58 Z. Attari et al.size and increased surface area, contributing to enhanced
dissolution and eventually increased bioavailability
(Kesisoglou et al., 2007; Kocbek et al., 2006; Liversidge and
Cundy, 1995). Broadly, there are two methods for preparation
of nanosuspension, bottom-up (precipitation) and top-down
(Rabinow, 2004;Merisko-Liversidge et al., 2003). The top down
technologies are based on particle fragmentation to submicron
units and include ballmilling andhigh-pressure homogenization
(Keck and Muller, 2006; Jacob et al., 2000). Top-down method
is widely accepted to reduce particle size of drug and proved to
be successful; however, combinative technologies are recently
used to produce even smaller particles or reduce the processing
time to prepare nanosuspension. Combinations of ball milling,
lyophilization or precipitation with high pressure homogeniza-
tion (HPH) are the reported methods under combinative tech-
nologies (Salazar et al., 2012a, 2013b).
Olmesartan medoxomil (OLM) is a selective AT1-subtype
angiotensin-II receptor antagonist used for the treatment of
hypertension (Warne and Jarvis, 2002). The aqueous solubility
of OLM is < 7.75 lg/ml and oral bioavailability of the tablet is
only 26% in healthy humans (Prajapati et al., 2013). The unab-
sorbed drug leads to gastrointestinal side effects such as
abdominal pain, dyspepsia, gastroenteritis and nausea. The
nanosuspension of OLM was reported to enhance its bioavail-
ability (Thakkar et al., 2011). In the present study, an effort was
made to prepare nanosuspension of OLM by a combination of
top down methods and evaluate the effectiveness of combina-
tive methods in enhancing the intestinal absorption of OLM.
2. Methods
2.1. Preparation of nanosuspension
The nanosuspensions of OLM were prepared by combinative
technologies. Two methods were employed in the present study
viz. ball milling followed by probe sonication and high speed
homogenization followed by probe sonication. Various concen-
trations of stabilizers such as PVA and Poloxamer 407 (P407)
were used to stabilize the nanosuspensions (Table 1). Brieﬂy,
30 mg of OLM was dispersed in 15 ml of stabilizer solution
and homogenized (Polytron PT 1300D, Singapore) or ball







1 BM1 Poloxamer 407 0.5 15
2 BM2 Poloxamer 407 0.5 10
3 BM3 Poloxamer 407 0.25 15
4 BM4 Poloxamer 407 0.25 10
5 BM5 Poloxamer 407 0.125 15
6 BM6 Poloxamer 407 0.125 10
7 BM7 Poloxamer 407 0.1 15
8 BM8 Poloxamer 407 0.1 10
9 BM9 PVA 0.5 30
10 BM10 PVA 0.25 30
11 BM11 PVA 0.25 15
12 HSH1 Poloxamer 407 0.125 15
13 HSH2 PVA 0.25 15
Figure 3 Particle size of nanosuspensions after conventional and
combinative technologies.
Table 2 Characterization of nanosuspensions of OLM.
S. no. Code Ball milling Ball milling + probe sonication
PS (nm) PDI PS (nm) PDI ZP (mV)
1 BM1 4275 0.443 707.8 0.495 23.6
2 BM2 1177 0.638 23.6
3 BM3 1418 0.770 1127 1.0 3.73
4 BM4 1178 0.275 3.56
5 BM5 1032 0.789 534.9 0.570 19.3
6 BM6 693.4 0.544 19.1
7 BM7 1360 0.660 469.9 0.439 19.1
8 BM8 732.5 0.478 18.6
9 BM9 1432 0.782 797.2 0.837 3.09
10 BM10 824.7 0.692 616.5 0.561 4.99
11 BM11 749.1 0.861 4.3
HSH HSH+ probe sonication
12 HSH1 2947 0.503 2816 0.640 4.96
13 HSH2 2380 0.511 509.4 0.450 21.3
Figure 4 Particle size and zeta potential of the selected nanosuspension, BM7 using Malvern zetasizer.
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Table 3 Drug content of OLM nanosuspension by external
standard method.
S. no. Group Area Drug amount (%)
1 Pure drug 34108 100
2 Nanosuspension 21509 63.06
60 Z. Attari et al.sonication. The dispersion was homogenized at 17,000 rpm for
30 min, whereas, ball milling was done at 400 rpm for 30 min
using 5 mm SS balls. The effect of variation in time of son-
ication (10, 15 or 30 min) on the particle size was evaluated.
2.2. Particle size, polydispersity index (PDI) and zeta potential
The particle size (PS), PDI and zeta potential (ZP) of the pre-
pared nanosuspensions were assessed using Malvern zetasizer.
The nanosuspension of OLM was selected based on particle
size and zeta potential. The selected nanosuspension was lyo-
philized using mannitol as a cryoprotectant to carry out FT-
IR, DSC and drug content.Figure 5 FT-IR spectra of OLM and2.3. HPLC method
The analytical method for ACV was developed and validated
as per the ICH Q2 (R1) guideline. The RP-HPLC–UV method
was employed to estimate the drug content in the nanosuspen-
sion and intestinal absorption. The method was validated by
injecting 20 ll of the standard drug samples at the ﬂow rate
of 0.5 ml per minute to the C18 ODS column. The mobile
phase consisted of a mix of acetonitrile:phosphate buffer, pH
6.2 (41:59 v/v). The peak of the drug was measured using a
UV-detector at 250 nM. The run time was 9 min and the reten-
tion time was 6.6 min. The chromatogram is shown in Fig. 1.
2.4. Drug content
The freeze dried nanosuspension was analyzed by dispersing a
weighed amount in methanol followed by sonication and ﬁlter-
ing through 0.22 lm ﬁlter. The amount of drug was determined
by HPLC. The drug content was determined by two methods,
external standard and calibration curve method (Fig. 2). The
equation for calibration curve is presented beneath.
y ¼ 291:26xþ 3287:4 ð1Þits freeze dried nanoformulation.
Table 4 Characteristic peaks of OLM nanoformulation and
pure drug in FT-IR spectra.










Aliphatic CAH stretch 2972 2966 2935
C‚O of carboxylic group 1706 1705 1707
CAN stretch 1474 1475 1458
In plane OAH bend 1389 1392 1371
CAOAC stretch 1028 1056 1055
Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension 612.5. Fourier transform-infrared spectroscopy (FT-IR) and
Differential Scanning Calorimetry (DSC)
The FT-IR spectra and DSC thermograms of the freeze-dried
OLM nanoformulation and pure drug were obtained to evalu-
ate the drug-excipient interaction and crystallinity of the drug
in the nano-system.
2.6. Ex vivo intestinal absorption – non-everted sac method
(Bothiraja et al., 2012; Shishu and Maheshwari, 2010)
Ex vivo studies were performed on fasted male Wistar rats
weighing 250–300 g.Figure 6 DSC thermograms of OLM aThe study was approved by the Institutional Animal Ethics
Committee (No.–IAEC/KMC/48/2014), Manipal University.
The animals were sacriﬁced and intestine (duodenum) was
isolated and washed with Kreb’s-Ringer solution. The non-
everted tissue of 6 cm length was tied at one end and ﬁlled with
1.1 ml drug/formulation solution containing 10 mg drug and
was tied at the other end, making the sac. The sac was
immersed in the Kreb’s-Ringer solution contained in the bea-
ker. The aliquots of 1 ml solution were removed and replaced
with Kreb’s-Ringer solution at 30, 45, 60, 90 and 120 min time
interval. The drug concentration in the aliquots was analyzed
using HPLC. The outcomes were analyzed statistically apply-
ing student’s t-test at p< 0.05. The permeability coefﬁcients
were determined using Eq. (2).
Papp ¼ dQ=dtþ 1=ðAþ C0Þ ð2Þ
The slope of the linear portion of the plot was considered
permeation ﬂux (dQ/dt).3. Results and discussion
3.1. Characterization of prepared nanosuspensions of OLM
The particle size was compared after ball milling/HSH and ball
milling/HSH along with probe sonication. It was found that a
combination of ball milling and probe sonication resulted in
smaller particles than ball milling alone (Fig. 3). HSH along
with probe sonication was also successful in case of P407 but
not with PVA. This indicates that ball milling or HSH (prend its freeze dried nanoformulation.
Figure 7 Ex vivo intestinal absorption of OLM using non-
everted intestinal sac method. *Indicates signiﬁcant difference in
variances of two groups at p< 0.05 using student’s t-test.
62 Z. Attari et al.milling) produces the crack on the surface of particle which
leads to smaller particle size after homogenization at high pres-
sure. Ball milling produced particles of size near to 1l which
further led to smaller particles after probe sonication in accor-
dance with the earlier report (Peterson, 2010). An increase in
the concentration of stabilizers increased the particle size.
The zeta potential of P407-stabilized nanosuspensions was
observed to be in the acceptable range (+20 to 20 mV) as
compared to PVA-stabilized nanosuspensions. The nanosus-
pension (BM7) stabilized with 0.1% P407 and 15 min probe
sonication after 30 min ball milling showed particle size of
469.9 nm and acceptable zeta potential of 19.1 mV (Table 2
and Fig. 4). Thus, BM7 was selected for further studies. The
particle size increased to 900 nm after lyophilization.
3.2. Drug content
The drug content of selected OLM nanosuspension (BM7) was
found to be 63.06% and 62.56% by external standard and
calibration curve methods, respectively (see Table 3).
3.3. FT-IR and DSC
There was no considerable change in peaks in the OLM
nanoformulation as compared to pure drug, which indicated
no interaction between drug and excipients (Fig. 5). The peaks
are depicted in Table 4 and complied with earlier reported
values (Sasidhar et al., 2013). In DSC thermograms, the
endotherm of pure drug was observed at 183 C, whereas the
endotherm decreased to 166 C in nanoformulation (Fig. 6).
This indicated that there was a slight decrease in the crys-
tallinity of OLM nanocrystals.
3.4. Ex vivointestinal absorption
The absorption was estimated through the duodenum (proxi-
mal part) of the intestine, as OLM mostly gets absorbed
through the duodenum (Kang et al., 2012). The drug
permeated across the intestinal wall and its concentration
was measured in the Kreb’s-Ringer solution. The absorption
of drug in nanosuspension was observed to be signiﬁcantly
increased as compared to pure drug (Fig. 7). The permeability
coefﬁcients of nanosuspension and pure drug were found to be
0.72 · 108 cm2/s and 0.18 · 108 cm2/s respectively. The
observations suggest that the reduction in particle size leadsto increase in the permeation of the drug particles and
eventually improves the absorption of the drug.4. Conclusion
It is observed in the present study that the combinative tech-
nologies reduce the particle size of the drug more efﬁciently
than the conventional approach with lesser processing time.
The prepared nanosuspension showed the optimum particle
size and zeta potential. In ex vivo intestinal absorption, the
absorption and permeability of OLM nanosuspension were
observed to be increased as compared to pure drug. This shows
that there was better reduction in particle size resulting in
increased surface area which increased the permeation and
eventually increased the absorption. However, pharmacoki-
netic and pharmacodynamic studies are required to further
support the ﬁnding.Acknowledgements
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